Michael Feld Sells 75 Shares of Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 75 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $152.80, for a total transaction of $11,460.00. Following the sale, the executive vice president owned 21,009 shares of the company’s stock, valued at $3,210,175.20. This represents a 0.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Tuesday, May 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $147.35, for a total value of $11,051.25.
• On Monday, April 27th, Michael Feld sold 74 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $151.94, for a total value of $11,243.56.

Becton, Dickinson and Company Price Performance

BDX stock opened at $156.06 on Friday. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The stock has a market cap of $43.00 billion, a price-to-earnings ratio of 39.51, a price-to-earnings-growth ratio of 11.04 and a beta of 0.22. The business has a fifty day moving average of $148.17 and a two-hundred day moving average of $170.75.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating the consensus estimate of $2.77 by $0.13. The business had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Ravenstone Capital Management Inc. purchased a new position in Becton, Dickinson and Company in the 1st quarter valued at approximately $7,465,000. Defilade Capital Management L.P. increased its position in shares of Becton, Dickinson and Company by 243.8% during the first quarter. Defilade Capital Management L.P. now owns 279,210 shares of the medical instruments supplier’s stock worth $43,900,000 after acquiring an additional 198,003 shares during the period. DV Trading LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at $236,000. Parallel Advisors LLC raised its stake in shares of Becton, Dickinson and Company by 16.7% in the first quarter. Parallel Advisors LLC now owns 4,071 shares of the medical instruments supplier’s stock valued at $640,000 after acquiring an additional 582 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in Becton, Dickinson and Company by 35.0% in the first quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier’s stock valued at $6,923,000 after purchasing an additional 11,414 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Bank of America dropped their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Weiss Ratings lowered shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Piper Sandler lowered their price objective on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Finally, Barclays upped their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $181.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.